STAT reports that the Biotechnology Innovation Organization (BIO) has joined a legal challenge against a US Medicare pilot programme that links drug prices to those in peer countries. The model is described as a test of the Trump administration’s most-favoured nation approach to drug pricing, but its impact is expected to be limited, according to STAT.
This legal action signals resistance from the biotech sector to government efforts to control drug costs by referencing international prices. For pharma and biotech executives, the outcome could shape future US pricing models and influence global pricing strategies.
